Abstract
s S239 all surviving participants at the Norwegian centre were eligible for inclusion. Cognitive function was assessed by means of a neuropsychological examination, focusing on selected cognitive domains: memory (Hopkins Verbal Learning Test Revised, Brief Visual Memory Test Revised), language (Verbal fluency, Boston Naming Test), attention (Digit span), processing speed and executive functions (Color-Word Interference Test, Trail Making Test). In addition premorbid intellectual capacity was estimated (National Adult Reading Test). Results: 37 of 44 eligible subjects could be included. 20 subjects received everolimus-based maintenance therapy, while 17 subjects received traditional CNI-based therapy. The mean age at time of assessment (3.2 years after HTx) was 55.1 years and 24.3% were women, with no differences between the study groups. The group as a whole showed cognitive dysfunction, especially with regard to attention, processing speed and memory. However, our initial analyses uncover no clinically relevant differences in cognitive functioning between the two study groups. Conclusion: Compared to the traditional CNI-based regimen, early elimination of CNI and introduction of everolimus, doesn’t seem to lead to clinically relevant unforeseen cognitive side effects after HTx.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have